EDTXF Spectral Diagnostics
Spectral Diagnostics (EDTXF) is expected to report earnings on November 6, 2026, before the market open.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Spectral Diagnostics
Spectral Medical Inc. develops and commercializes theranostic treatment for severe sepsis. The company's products include Endotoxin Activity Assay, a rapid diagnostic test for detection of components of gram negative bacterial cell wall; and Toraymyxin, a therapeutic hemoperfusion device for the treatment of sepsis that removes endotoxin from the bloodstream. Spectral Medical Inc., formerly known as Spectral Diagnostics Inc., is headquartered in Toronto, Canada.